## Abbreviations
[CrossRef]
* Wang and DuBois (2013) Wang, D.; DuBois, R.N. The Role of Anti-Inflammatory Drugs in Colorectal Cancer. _Annu. Rev. Med._**2013**, _64_, 131-144. [CrossRef]
* Ensign et al. (2012) Ensign, L.M. ; Cone, R.; Hanes, J. Oral Drug Delivery with Polymeric Nanoparticles: The Gastrointestinal Mucus Barriers. _Adv. Drug Deliv. Rev._**2012**, _64_, 557-570. [CrossRef]
* Dulai et al. (2014) Dulai, P.S. ; Siegel, C.A. ; Colombel, J.-F.; Sandborn, W.J. ; Peyrin-Biroulet, L. Systematic Review: Monotherapy with Antitumour Necrosis Factor \(\alpha\) Agents versus Combination Therapy with an Immunosuppressive for IBD. _Gut_**2014**, _63_, 1843-1853. [CrossRef]
* Sandborn and Hanauer (1999) Sandborn, W.J. ; Hanauer, S.B. Antitumor Necrosis Factor Therapy for Inflammatory Bowel Disease: A Review of Agents, Pharmacology, Clinical Results, and Safety. _Inflamm. Bowel Dis._**1999**, \(5\), 119-133. [CrossRef] [PubMed]
* Navaneethan and Lashner (2013) Navaneethan, U.; Lashner, B.A. Effects of Immunosuppression and Liver Transplantation on Inflammatory Bowel Disease in Patients with Primary Sclerosing Cholangitis. _Clin. Gastroenterol. Hepatol._**2013**, _11_, 524-525. [CrossRef] [PubMed]
* Miao et al. (2017) Miao, L.; Guo, S.; Lin, C.M. ; Liu, Q.; Huang, L. Nanoformulations for Combination or Cascade Anticancer Therapy. _Adv. Drug Deliv. Rev._**2017**, _115_, 3-22. [CrossRef] [PubMed]
* Qiu et al. (2018) Qiu, N.; Gao, J.; Liu, Q.; Wang, J.; Shen, Y. Enzyme-Responsive Charge-Reversal Polymer-Mediated Effective Gene Therapy for Intraperitoneal Tumors. _Biomacromolecules_**2018**, _19_, 2308-2319. [CrossRef]
* Chen et al. (2019) Chen, Y.; Song, W.; Shen, L.; Qiu, N.; Hu, M.; Liu, Y.; Liu, Q.; Huang, L. Vasodilator Hydralazine Promotes Nanoparticle Penetration in Advanced Desmoplastic Tumors. _ACS Nano_**2019**, _13_, 1751-1763. [CrossRef]
* Li et al. (2020) Li, X.; Lu, C.; Yang, Y.; Yu, C.; Rao, Y. Site-Specific Targeted Drug Delivery Systems for the Treatment of Inflammatory Bowel Disease. _Biomed. Pharmacother._**2020**, _129_, 110486. [CrossRef]
* Di Sabatino et al. (2011) Di Sabatino, A.; Biancheri, P.; Rovedatti, L.; MacDonald, T.T. ; Corazza, G.R. Recent Advances in Understanding Ulcerative Colitis. _Intern. Emerg. Med._**2011**, \(7\), 103-111. [CrossRef]
* Xiao and Merlin (2012) Xiao, B.; Merlin, D. Oral Colon-Specific Therapeutic Approaches toward Treatment of Inflammatory Bowel Disease. _Expert Opin. Drug Deliv._**2012**, \(9\), 1393-1407. [CrossRef]
* Sun et al. (2020) Sun, T.; Kwong, C.H. ; Gao, C.; Wei, J.; Yue, L.; Zhang, J.; Ye, R.D. ; Wang, R. Amelioration of Ulcerative Colitis Via Inflammatory Regulation by Macrophage-Biomimetic Nanomedicine. _Thernostics_**2020**, _10_, 10106-10119. [CrossRef]
* Chung et al. (2020) Chung, C.H. ; Jung, W.; Keum, H.; Kim, T.W. ; Jon, S. Nanoparticles Derived from the Natural Antioxidant Rosmarinic Acid Ameliorate Acute Inflammatory Bowel Disease. _ACS Nano_**2020**, _14_, 6887-6896. [CrossRef]
* Xu et al. (2015) Xu, B.; Watkins, R.; Wu, L.; Zhang, C.; Davis, R. Natural Product-Based Nanomedicine: Recent Advances and Issues. _Int. J. Nanomed._**2015**, _10_, 6055. [CrossRef] [PubMed]
* Khaaji et al. (2019) Khaaji, M.; Zamani, M.; Golizadeh, M.; Bavi, O. Inorganic Nanomaterials for Chemo/Photothermal Therapy: A Promising Horizon on Effective Cancer Treatment. _Biophys. Rev._**2019**, _11_, 335-352. [CrossRef] [PubMed]
* Sowmya et al. (2012) Sowmya, C.; Reddy, C.S. ; Sandhya, R.; Keerthi, K. Colon Specific Drug Delivery Systems: A review of pharmaceutical approaches with Cur-Rent Trends. _Int. Res. J. Pharm._**2012**, \(3\), 45-57. * Pan et al. (2023) Pan, Q.; Lu, Y.; Xie, L.; Wu, D.; Liu, R.; Gao, W.; Luo, K.; He, B.; Pu, Y. Recent Advances in Boosting EGFR Tyrosine Kinase Inhibitors-Based Cancer Therapy. _Mol. Pharm._**2023**, _20_, 829-852. [CrossRef]
* Zhang et al. (2023) Zhang, M.; Wen, Y.; Huang, Z.; Qin, X.; Zhou, M.; Xiao, D.; Cui, W.; Liu, Z.; Lin, Y.